1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"RFA-HL-26-019: Catalyze Product Definition Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33 - Clinical Trial Not Allowed)" is currently closed and not accepting applications.
RFA-HL-26-019: Catalyze Product Definition Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33 - Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). Supports small businesses in developing medical device prototypes and conducting disease target identification and assay development.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed) Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93.
838 -- Lung Diseases Research 93. 837 -- Cardiovascular Diseases Research 93. 233 -- National Center on Sleep Disorders Research 93.
839 -- Blood Diseases and Resources Research Last Updated: November 22, 2024 View version history on Grants.
gov The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship.
This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test device prototypes, identify diagnostic disease targets and develop associated assays, and develop research... tools to treat HLBS diseases and disorders. This is a phased initiative for early stage projects.
The R61 phase provides support to identify and test initial prototype designs, to identify a disease target and generate experimental design, and to identify, test and pilot research tools.
The R33 phase provides support for continued prototype development and testing, in addition to modifying design features and user feedback, diagnostic product generation, exploration of assay components, and characterization of a load design, and research tool improvement, large trial testing and data integration.
Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs.
This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.
Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Public and state institutions of higher education Independent school districts Private institutions of higher education Public and Indian housing authorities City or township governments Federally recognized Native American tribal governments Special district governments For-profit organizations other than small businesses Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Grantor contact information See Section VII.
Agency Contacts within the full opportunity announcement for all other inquires. File name Description Last updated RFA-HL-26-019-Full-Announcement. html RFA-HL-26-019 Full Announcement Text Nov 22, 2024 04:56 PM UTC Link to additional information https://grants.
nih. gov/grants/guide/rfa-files/RFA-HL-26-019. html Closing: December 23, 2027 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Small businesses in the U.S. with fewer than 500 employees. Confirm the full requirements in the official notice before applying.
The published deadline was March 31, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
RFA-HL-26-019: Catalyze Product Definition Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33 - Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article